| Autor: |
Rodríguez-Castañón JM; Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición salvador Zubirán, Mexico City, Mexico., Mcnaughton A; Division of Infectious Diseases, Queen's University, Kingston, Canada Kingston, Canada., Cárdenas-Ochoa A; Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición salvador Zubirán, Mexico City, Mexico., Fuentes-Romero LL; Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición salvador Zubirán, Mexico City, Mexico., Viveros-Rogel M; Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición salvador Zubirán, Mexico City, Mexico., Vergara-Mendoza M; Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición salvador Zubirán, Mexico City, Mexico., Tello-Mercado AC; Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición salvador Zubirán, Mexico City, Mexico., Leal-Gutiérrez G; Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición salvador Zubirán, Mexico City, Mexico., Romero-Carvajal JJ; Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición salvador Zubirán, Mexico City, Mexico., Cázares-Lara J; Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición salvador Zubirán, Mexico City, Mexico., Camiro-Zúñiga A; Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición salvador Zubirán, Mexico City, Mexico., Jaramillo-Jante R; Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición salvador Zubirán, Mexico City, Mexico., Antuna-Puente B; Instituto Nacional de Medicina Genómica, Mexico City, Mexico., Galindo-Fraga A; Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición salvador Zubirán, Mexico City, Mexico., Soto-Ramírez LE; Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición salvador Zubirán, Mexico City, Mexico., Sierra-Madero JG; Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición salvador Zubirán, Mexico City, Mexico., Perez-Patrigeon S; Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición salvador Zubirán, Mexico City, Mexico.; Division of Infectious Diseases, Queen's University, Kingston, Canada Kingston, Canada. |
| Abstrakt: |
We present a cohort of individuals who reached CD4 + T cell counts of greater than 1,000 cells/mm 3 (Hypers) after starting antiretroviral treatment (ART) and compared them with those who reached between 350 and 999 CD4 + T cells/mm 3 (Concordants). Demographic data, immune recovery kinetics, T CD4 + subset phenotypes, and integrated HIV DNA were analyzed. Data from individuals living with HIV on their first ART regimen and after 48 months of follow-up were obtained. Immune phenotype by Flow Cytometry analysis on whole blood was performed, cytokines were measured, and integrated HIV-1 DNA was measured by polymerase chain reaction. From a total of 424 individuals, 26 Hypers (6.1%), 314 Concordants (74.1%), and 84 (19.8%) discordants were identified. Hypers had a higher proportion of CD4 + -naive (Nv) T cells (37.6 vs. 24.8, p < .05), and a low proportion of CD4 + effector memory T cells (27.9 vs. 39.4, p < .05), with similar results found in CD8 + T cells. Hypers demonstrated a higher percentage of CD4 + CD45RA + CD31 neg cells with a lower response to interleukin-2 stimulation and a lower integrated HIV-1 DNA/CD4 ratio (1.2 vs. 2.89, p < .05). In Hypers, T cell recovery occurs very early after initiation of ART. Following this initial recovery state, their CD4 + T cell level homeostasis seems to be driven by nonthymic-central-Nv cells. This exceptional recovery is associated with a lower HIV reservoir, which may be related to an increase in noninfected CD4 + T cells. These patients could then be eligible candidates for cure trials. |
